Last updated on November 2019

A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata


Brief description of study

This study is designed to select up to two doses of baricitinib (referred to as low dose and high dose) and assess their efficacy and safety for the treatment of severe or very severe alopecia areata.

Clinical Study Identifier: NCT03570749

Find a site near you

Start Over